AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32521449 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech Recognition (SR)
Number of subjects: 10
Study 32521449 — intervention group
Group type: COMPARATOR
Intervention: Typing
Number of subjects: 10
Study 36047376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node mapping using indocyanine green
Number of subjects: 0
Study 36047376 — intervention group
Group type: COMPARATOR
Intervention: Conventional lymph node dissection
Number of subjects: 0
Study 33663487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) and sulfasalazine (SSZ) for the first 12 weeks, then remove TNFi but continue other treatments for the next 48 weeks.
Number of subjects: 0
Study 33663487 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintain TNFi + MTX for 60 weeks.
Number of subjects: 0
Study 33663487 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintain TNFi + MTX for the first 12 weeks, then remove TNFi but continue MTX monotherapy for the next 48 weeks.
Number of subjects: 0
Study 33663487 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cost per reducing 1 case of relapse; patient reported intolerance to the treatment; adverse events; change of mean disease activity measured by DAS28, CDAI, and SDAI; the proportion of modified Sharp score increase < 0.3; ultrasound-detected remission in hands; Health Assessment Questionnaire Disability Index (HAQ-DI); health-related quality of life (EQ-5D-5L and SF-6D).
Number of subjects: 0
Study 32068484 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg vibegron
Number of subjects: 1518
Study 32068484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1518
Study 32068484 — intervention group
Group type: COMPARATOR
Intervention: Extended-release 4 mg tolterodine
Number of subjects: 1518
Study 34599540 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 45
Study 34599540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 33030662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided reduction (POCUS)
Number of subjects: 108
Study 33030662 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided reduction
Number of subjects: 108
Study 33532874 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella supplementation (1500 mg/day for 8 weeks)
Number of subjects: 84
Study 33532874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 36227170 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training (PMT)
Number of subjects: 145
Study 36227170 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative and Proactive Solutions (CPS)
Number of subjects: 145
Study 36227170 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (PMT and CPS)
Number of subjects: 145
Study 33527220 — intervention group
Group type: EXPERIMENTAL
Intervention: Supra-umbilical transverse incision
Number of subjects: 0
Study 33527220 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical midline incisional closure with small bites technique using non-absorbable suture (#0 or 2–0 PDS II with SH or CT-2 needle)
Number of subjects: 0
Study 33527220 — intervention group
Group type: COMPARATOR
Intervention: Off-midline extraction technique
Number of subjects: 0
Study 35418511 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + LBS
Number of subjects: 15
Study 35418511 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + UBS
Number of subjects: 15
Study 33550259 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention programme
Number of subjects: 0
Study 33550259 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care (UCC)
Number of subjects: 0
Study 32892606 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS-TKA
Number of subjects: 90
Study 32892606 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI-TKA
Number of subjects: 90
Study 32892606 — intervention group
Group type: COMPARATOR
Intervention: CI-TKA
Number of subjects: 90
Study 35476888 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 µg/kg
Number of subjects: 60
Study 35476888 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 60
Study 35476888 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 60
Study 33097351 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.1 mg/kg plus fentanyl 1 μg/kg IV
Number of subjects: 81
Study 33097351 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.1 mg/kg plus fentanyl 1 μg/kg IV
Number of subjects: 81
Study 35101115 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly (28-day) INJ-BUP
Number of subjects: 952
Study 35101115 — intervention group
Group type: COMPARATOR
Intervention: Daily SL-BUP/NLX
Number of subjects: 952
Study 35101115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 952
Study 32840337 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin plus Solifenacin
Number of subjects: 62
Study 32840337 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin plus Tolterodine
Number of subjects: 62
Study 32840337 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin alone
Number of subjects: 62
Study 35914112 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 74
Study 35914112 — intervention group
Group type: COMPARATOR
Intervention: General health education (HT)
Number of subjects: 74
Study 33419461 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy A1 (gold standard): Individuals receive information and study material by mail with instructions on how to produce a saliva sample and return it. Samples tested for SARS‐CoV‐2 using RT‐LAMP.
Number of subjects: 10000
Study 33419461 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy A2: Individuals receive information and study material by mail with instructions on how to produce their own and household members' saliva samples. Samples tested for SARS‐CoV‐2 using RT‐LAMP.
Number of subjects: 10000
Study 33419461 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy B1: Individuals receive information on completing a pre‐screening questionnaire. Only those whose score crosses a threshold receive additional study material for saliva sampling. Samples tested for SARS‐CoV‐2 using RT‐LAMP.
Number of subjects: 10000
Study 33419461 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy B2: Individuals receive information on completing a pre‐screening questionnaire. Only those whose score crosses a threshold receive additional study material for saliva sampling from all household members. Samples tested for SARS‐CoV‐2 using RT‐LAMP.
Number of subjects: 10000
Study 33419461 — intervention group
Group type: COMPARATOR
Intervention: Passive surveillance (status quo): Currently practiced approach for comparison.
Number of subjects: 10000
Study 32388632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone intervention prior to the first urogynecologic visit; included a questionnaire about history and symptoms and prompted patients to complete a bladder diary.
Number of subjects: 108
Study 32388632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contact prior to the visit).
Number of subjects: 108
Study 32041164 — intervention group
Group type: EXPERIMENTAL
Intervention: SIESERIES - two series of three 'all-out' repeated 10-s bouts, separated by 30-s recovery and 18-min recovery between series
Number of subjects: 12
Study 32041164 — intervention group
Group type: COMPARATOR
Intervention: SIE6×10"/4' - six 'all-out' repeated 10-s bouts, interspersed with 4-min recovery
Number of subjects: 12
Study 32041164 — intervention group
Group type: EXPERIMENTAL
Intervention: SIESERIES
Number of subjects: 12
Study 33113028 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted plasma Hcy levels
Number of subjects: 15666
Study 33113028 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up sensitivity analyses
Number of subjects: 15666
Study 33113028 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-Egger intercept test
Number of subjects: 15666
Study 32881968 — intervention group
Group type: EXPERIMENTAL
Intervention: ALFA-adjuvanted vaccine
Number of subjects: 0
Study 32881968 — intervention group
Group type: COMPARATOR
Intervention: Alum-adjuvanted vaccine
Number of subjects: 0
Study 32881968 — intervention group
Group type: EXPERIMENTAL
Intervention: MPLA-liposome-alum adjuvanted gp120
Number of subjects: 0
Study 34470144 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer locked continuous suturing (Group 1)
Number of subjects: 194
Study 34470144 — intervention group
Group type: COMPARATOR
Intervention: Single-layer unlocked continuous suturing (Group 2)
Number of subjects: 194
Study 34470144 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 194
Study 34470144 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without uterine niche development
Number of subjects: 194
Study 34470144 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with uterine niche development
Number of subjects: 194
Study 34470144 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without uterine niche
Number of subjects: 194
Study 34470144 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with uterine niche
Number of subjects: 194
Study 34830654 — intervention group
Group type: EXPERIMENTAL
Intervention: Early platelet function‐guided surgery
Number of subjects: 156
Study 34830654 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery
Number of subjects: 156
Study 34830654 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 156
Study 33739333 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-minute mindful breathing practice performed three times per day for three months
Number of subjects: 0
Study 33739333 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35637185 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinatorial pharmacogenomic testing
Number of subjects: 149
Study 35637185 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 149
Study 32007099 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based PEEP titration
Number of subjects: 320
Study 32007099 — intervention group
Group type: COMPARATOR
Intervention: Standard practice ventilation (SPV)
Number of subjects: 320
Study 36012036 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 72
Study 36012036 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Continuous Exercise (HICE)
Number of subjects: 72
Study 36012036 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 72
Study 32035487 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W) with possible increase to 150 mg Q2W at Week 12
Number of subjects: 413
Study 32035487 — intervention group
Group type: COMPARATOR
Intervention: Usual care (ezetimibe, fenofibrate, or no additional lipid-lowering therapy)
Number of subjects: 413
Study 36264605 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM-based educational intervention delivered through WeChat, consisting of 4 individual educational sessions and educational information sharing.
Number of subjects: 118
Study 36264605 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 118
Study 34236770 — intervention group
Group type: EXPERIMENTAL
Intervention: Imlifidase
Number of subjects: 39
Study 32382922 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAT combined with SCTG and EMD
Number of subjects: 20
Study 32382922 — intervention group
Group type: COMPARATOR
Intervention: MCAT with SCTG
Number of subjects: 20
Study 35426822 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelfoam carrier soaked in 1 ml of triamcinolone acetonide (40 mg)
Number of subjects: 100
Study 35426822 — intervention group
Group type: COMPARATOR
Intervention: Gelfoam carrier soaked in normal saline
Number of subjects: 100
Study 34470790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tweets stating e‐cigarettes are just as or more harmful than smoking
Number of subjects: 2400
Study 34470790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tweets stating e‐cigarettes are completely harmless
Number of subjects: 2400
Study 34470790 — intervention group
Group type: COMPARATOR
Intervention: Control condition of tweets about physical activity
Number of subjects: 2400
Study 35739010 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 786
Study 35739010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 786
Study 33347390 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-framed messages
Number of subjects: 62
Study 33347390 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-framed messages
Number of subjects: 62
Study 33347390 — intervention group
Group type: COMPARATOR
Intervention: No messages (control)
Number of subjects: 62
Study 35956380 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Score label
Number of subjects: 354
Study 35956380 — intervention group
Group type: EXPERIMENTAL
Intervention: HFL label
Number of subjects: 354
Study 35956380 — intervention group
Group type: EXPERIMENTAL
Intervention: Manga label (sugar-specific)
Number of subjects: 354
Study 35956380 — intervention group
Group type: EXPERIMENTAL
Intervention: Comic label (sugar-specific)
Number of subjects: 354
Study 35956380 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no label)
Number of subjects: 354
Study 34445031 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula containing 5HMO-Mix (5.75 g/L total, comprising 52% 2′‐fucosyllactose, 13% 3‐fucosyllactose, 26% lacto‐N‐tetraose, 4% 3′‐sialyllactose, and 5% 6′‐sialyllactose)
Number of subjects: 341
Study 34445031 — intervention group
Group type: COMPARATOR
Intervention: Infant formula without HMOs (Control)
Number of subjects: 341
Study 34445031 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed infants
Number of subjects: 341
Study 34459976 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 118
Study 34459976 — intervention group
Group type: COMPARATOR
Intervention: Placebo (decaffeinated coffee)
Number of subjects: 118
Study 33340767 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) with an intensity of 2 mA for 20 min/day for five consecutive sessions
Number of subjects: 36
Study 33340767 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 36
Study 33340767 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 36
Study 32598997 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (HIIT)
Number of subjects: 35
Study 32598997 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 35
Study 32598997 — intervention group
Group type: COMPARATOR
Intervention: Sham placebo-control (PLA)
Number of subjects: 35
Study 32598997 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT
Number of subjects: 35
Study 32598997 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 35
Study 35576354 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy with or without robotic assistance
Number of subjects: 0
Study 35576354 — intervention group
Group type: COMPARATOR
Intervention: Vaginal mesh hysteropexy kit
Number of subjects: 0
Study 35576354 — intervention group
Group type: COMPARATOR
Intervention: Traditional native tissue repairs
Number of subjects: 0
Study 32328773 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivor Healthcare Passport
Number of subjects: 126
Study 32328773 — intervention group
Group type: COMPARATOR
Intervention: No Survivor Healthcare Passport
Number of subjects: 126
Study 36323130 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 25 mg add-on
Number of subjects: 0
Study 36323130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35565903 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa oleifera (MO) dry leaf powder, 6 × 400 mg capsules/day for 12 weeks
Number of subjects: 65
Study 35565903 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 65
Study 35565903 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa oleifera (MO) dry leaf powder
Number of subjects: 65
Study 33491305 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI increase (per SD)
Number of subjects: 8293
Study 33491305 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAIL
Number of subjects: 8293
Study 33491305 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP‐1
Number of subjects: 8293
Study 33684023 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich meal, snack, and bread (INT1)
Number of subjects: 67
Study 33684023 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular meal (INT2)
Number of subjects: 67
Study 33684023 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 67
Study 33001135 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (arm A)
Number of subjects: 148
Study 33001135 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (arm B)
Number of subjects: 148
Study 33001135 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (arm C)
Number of subjects: 148
Study 35708696 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus Active Surveillance (AS)
Number of subjects: 227
Study 35708696 — intervention group
Group type: COMPARATOR
Intervention: Active Surveillance (AS)
Number of subjects: 227
Study 33814890 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm Cycling Exercise (ACE)
Number of subjects: 13
Study 33814890 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 13
Study 33814890 — intervention group
Group type: COMPARATOR
Intervention: ACE
Number of subjects: 13
Study 34996409 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cerclage wires (CW)
Number of subjects: 42
Study 34996409 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cerclage wires (CW)
Number of subjects: 42
Study 34996409 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 2 CW and 3 CW
Number of subjects: 42
Study 32097051 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dry powder mannitol
Number of subjects: 333
Study 32097051 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 333
Study 35852013 — intervention group
Group type: EXPERIMENTAL
Intervention: Allium sativum (garlic extract)
Number of subjects: 66
Study 35852013 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca [OH]2)
Number of subjects: 66
Study 35852013 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ca (OH)2 and Allium sativum
Number of subjects: 66
Study 35852013 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic
Number of subjects: 66
Study 35852013 — intervention group
Group type: COMPARATOR
Intervention: Mechanical instrumentation
Number of subjects: 66
Study 33346121 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS to the dmPFC
Number of subjects: 52
Study 33346121 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 52
Study 33346121 — intervention group
Group type: COMPARATOR
Intervention: HD-tDCS to the rTPJ
Number of subjects: 52
Study 33346121 — intervention group
Group type: COMPARATOR
Intervention: Age/sex control task
Number of subjects: 52
Study 32955451 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided web-based counseling skills course
Number of subjects: 60
Study 35301359 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified immersive virtual reality environment
Number of subjects: 0
Study 35301359 — intervention group
Group type: COMPARATOR
Intervention: Text and images
Number of subjects: 0
Study 32267348 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin added to insulin therapy
Number of subjects: 47
Study 32267348 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued insulin therapy)
Number of subjects: 47
Study 33399385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided recruitment manoeuvres
Number of subjects: 40
Study 33399385 — intervention group
Group type: COMPARATOR
Intervention: Conventional recruitment manoeuvres
Number of subjects: 40
Study 35388589 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% TXA serum
Number of subjects: 18
Study 35388589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 32843496 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy plus coronary artery bypass graft surgery (CABG)
Number of subjects: 1212
Study 32843496 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 1212
Study 32843496 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in LVEF >10%
Number of subjects: 1212
Study 32843496 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomisation to CABG
Number of subjects: 1212
Study 33932873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling (CG)
Number of subjects: 30
Study 33932873 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (RG)
Number of subjects: 30
Study 33932873 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study 32691727 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus+MMF
Number of subjects: 543
Study 32691727 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 543
Study 32691727 — intervention group
Group type: COMPARATOR
Intervention: CYC
Number of subjects: 543
Study 36186156 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based imagery rescripting intervention
Number of subjects: 15
Study 32955088 — intervention group
Group type: EXPERIMENTAL
Intervention: RZF 400 mg QWk
Number of subjects: 207
Study 32955088 — intervention group
Group type: EXPERIMENTAL
Intervention: RZF 400/200 mg QWk
Number of subjects: 207
Study 32955088 — intervention group
Group type: COMPARATOR
Intervention: CAS 70 mg loading dose followed by 50 mg daily for ≤4 weeks
Number of subjects: 207
Study 32721237 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage-Cryosurgery
Number of subjects: 117